Phase I CY-219 CAR-T Cell Injection for Relapsed/Refractory B-Cell Lymphoma
ClinicalTrials.gov Studies
Summary
The National Institutes of Health registered a Phase I clinical study (NCT07539688) evaluating the safety and efficacy of CY-219 CAR-T cell injection in patients with relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma and transformed indolent B-cell lymphoma. The open-label, single-arm trial is sponsored by Changebridge Pharmaceutical Co., Ltd. and enrolls patients meeting specific disease criteria.
“This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.”
What changed
A new Phase I clinical trial has been registered on ClinicalTrials.gov under NCT07539688. The study will evaluate CY-219 CAR-T cell therapy in patients with relapsed/refractory B-cell lymphoma using an open-label, single-arm design.
Healthcare providers treating patients with relapsed or refractory B-cell lymphoma may wish to inform eligible patients about this trial as a potential treatment option. The inclusion and exclusion criteria specify DLBCL, indolent B-cell lymphoma transformed to large cell lymphoma, while explicitly excluding Richter transformation, THRLBCL, and Burkitt lymphoma.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
Phase 1 NCT07539688 Kind: PHASE1 Apr 20, 2026
Abstract
This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.
Conditions: Relapsed/Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Inert B-cell Lymphoma Transformed Into Large B-cell Lymphoma (Excluding Richter Transformation, THRLBCL, and BL)
Interventions: CY-219 CAR-T
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.